- Home
- CRIS vs ENLV Comparison
CRIS vs ENLV Comparison
Compare CRIS & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- ENLV
- Stock Information
- Founded
- CRIS 2000
- ENLV 2005
- Country
- CRIS United States
- ENLV Israel
- Employees
- CRIS N/A
- ENLV N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- ENLV Health Care
- Exchange
- CRIS Nasdaq
- ENLV Nasdaq
- Market Cap
- CRIS 21.3M
- ENLV 23.7M
- IPO Year
- CRIS 2000
- ENLV 1995
- Fundamental
- Price
- CRIS $2.37
- ENLV $0.97
- Analyst Decision
- CRIS Strong Buy
- ENLV Strong Buy
- Analyst Count
- CRIS 2
- ENLV 2
- Target Price
- CRIS $16.50
- ENLV $10.00
- AVG Volume (30 Days)
- CRIS 76.2K
- ENLV 46.3K
- Earning Date
- CRIS 07-31-2025
- ENLV 05-30-2025
- Dividend Yield
- CRIS N/A
- ENLV N/A
- EPS Growth
- CRIS N/A
- ENLV N/A
- EPS
- CRIS N/A
- ENLV N/A
- Revenue
- CRIS $11,202,000.00
- ENLV N/A
- Revenue This Year
- CRIS $0.93
- ENLV N/A
- Revenue Next Year
- CRIS $8.10
- ENLV N/A
- P/E Ratio
- CRIS N/A
- ENLV N/A
- Revenue Growth
- CRIS 14.17
- ENLV N/A
- 52 Week Low
- CRIS $1.02
- ENLV $0.81
- 52 Week High
- CRIS $9.72
- ENLV $1.76
- Technical
- Relative Strength Index (RSI)
- CRIS 59.94
- ENLV 49.07
- Support Level
- CRIS $2.23
- ENLV $0.93
- Resistance Level
- CRIS $2.63
- ENLV $0.98
- Average True Range (ATR)
- CRIS 0.18
- ENLV 0.05
- MACD
- CRIS 0.03
- ENLV -0.00
- Stochastic Oscillator
- CRIS 67.09
- ENLV 43.09
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.